Investigation of +405 and -460 polymorphisms of vascular endothelial growth factor in psoriasis and short-term responsiveness to efalizumab therapy

Dermatology

Volumn 217, Issue 3, 2008, Pages 201-202

  Stefanaki, I ^a,b   Dimisianos, G ^a   Antoniou, C ^a   Katsambas, A ^a   Stratigos, A ^a  

^a UNIVERSITY OF ATHENS   (Greece)

^b ANDREAS SYGROS HOSPITAL   (Greece)

Author keywords

Efalizumab; Psoriasis; Vascular endothelial growth factor

Indexed keywords

ANTIPSORIASIS AGENT; CYCLOSPORIN A; EFALIZUMAB; ETRETIN; METHOTREXATE; VASCULOTROPIN;

CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; GENETIC POLYMORPHISM; GENOTYPE; HUMAN; LETTER; MALE; PRIORITY JOURNAL; PSORIASIS VULGARIS; TREATMENT RESPONSE; ULTRAVIOLET B RADIATION; UNSPECIFIED SIDE EFFECT;

ANTIBODIES, MONOCLONAL; FEMALE; HUMANS; MALE; POLYMORPHISM, SINGLE NUCLEOTIDE; PSORIASIS; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 53549108324     PISSN: 10188665     EISSN: None     Source Type: Journal    
DOI: 10.1159/000141651     Document Type: Letter

References (13)

1. Creamer D, Allen MH, Sousa A, Poston R, Barker JN: Localization of endothelial proliferation and microvascular expansion in active plaque psoriasis. Br J Dermatol 1997;136:859-865.
2. Detmar M, Brown LF, Claffey KP, Yeo KT, Kocher O, Jackman RW, Berse B, Dvorak HF: Overexpression of vascular permeability factor/vascular endothelial growth factor and its receptors in psoriasis. J Exp Med 1994;180:1141-1146.
3. Creamer D, Allen MH, Groves RW, Barker JN: Circulating vascular permeability factor/vascular endothelial growth factor in erythroderma. Lancet 1996;348:1101.
4. Bhushan M, McLaughlin B, Weiss JB, Griffiths CE: Levels of endothelial cell stimulating angiogenesis factor and vascular endothelial growth factor are elevated in psoriasis. Br J Dermatol 1999;141:1054-1060.
5. Young HS, Summers AM, Bhushan M, Brenchley PE, Griffiths CE: Single-nucleotide polymorphisms of vascular endothelial growth factor in psoriasis of early onset. J Invest Dermatol 2004;122:209-215.
6. Barile S, Medda E, Nistico L, Bordignon V, Cordiali-Fei P, Carducci M, Rainaldi A, Marinelli R, Bonifati C: Vascular endothelial growth factor gene polymorphisms increase the risk to develop psoriasis. Exp Dermatol 2006;15:368-376.
7. Jullien D, Prinz JC, Langley RG, Caro I, Dummer W, Joshi A, Dedrick R, Natta P: T-cell modulation for the treatment of chronic plaque psoriasis with efalizumab (Raptiva): mechanisms of action. Dermatology 2004;208:297-306.
8. Young HS, Summers AM, Read IR, Fairhurst DA, Plant DJ, Campalani E, Smith CH, Barker JN, Detmar MJ, Brenchley PE, Griffiths CE: Interaction between genetic control of vascular endothelial growth factor production and retinoid responsiveness in psoriasis. J Invest Dermatol 2006;126:453-459.
9. Rottman JB, Smith TL, Ganley KG, Kikuchi T, Krueger JG: Potential role of the chemokine receptors CXCR3, CCR4, and the integrin alphaEbeta7 in the pathogenesis of psoriasis vulgaris. Lab Invest 2001;81:335-347.
10. Giustizieri ML, Mascia F, Frezzolini A, De PitàO, Chinni LM, Giannetti A, Girolomoni G, Pastore S: Keratinocytes from patients with atopic dermatitis and psoriasis show a distinct chemokine production profile in response to T cell-derived cytokines. J Allergy Clin Immunol 2001;107:871-877.
11. Deleuran M, Buhl L, Ellingsen T, Harada A, Larsen CG, Matsushima K, Deleuran B: Localization of monocyte chemotactic and activating factor (MCAF/MCP-1) in psoriasis. J Dermatol Sci 1996;13:228-236.
12. Tugues S, Fernandez-Varo G, Muñoz-Luque J, Ros J, Arroyo V, Rodés J, Friedman SL, Carmeliet P, Jiménez W, Morales-Ruiz M: Antiangiogenic treatment with sunitinib ameliorates inflammatory infiltrate, fibrosis, and portal pressure in cirrhotic rats. Hepatology 2007;46:1919-1926.
13. Kasselman LJ, Kintner J, Sideris A, Pasnikowski E, Krellman JW, Shah S, Rudge JS, Yancopoulos GD, Wiegand SJ, Croll SD: Dexamethasone treatment and ICAM-1 deficiency impair VEGF-induced angiogenesis in adult brain. J Vasc Res 2007;44:283-291.